Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MoonLake Immunotherapeutics - Class A Ordinary Shares
(NQ:
MLTX
)
16.15
-0.10 (-0.62%)
Streaming Delayed Price
Updated: 12:55 PM EST, Jan 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MoonLake Immunotherapeutics - Class A Ordinary Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
↗
October 16, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week...
Via
Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
October 16, 2023
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.
Via
Benzinga
Where MoonLake Stands With Analysts
↗
October 16, 2023
Via
Benzinga
The Latest Analyst Ratings for MoonLake
↗
September 18, 2023
Via
Benzinga
Expert Ratings for MoonLake
↗
August 31, 2023
Via
Benzinga
10 Analysts Have This to Say About MoonLake
↗
August 14, 2023
Via
Benzinga
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
↗
October 16, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session.
Via
Benzinga
Topics
Stocks
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
↗
October 16, 2023
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.
Via
Investor's Business Daily
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
October 15, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
Analyst Expectations for MoonLake's Future
↗
July 26, 2023
Via
Benzinga
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
October 11, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
↗
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
These 8 Stocks Are Outperforming Nvidia In 2023
↗
September 18, 2023
Carvana has surged 1,001%, leading huge winners this year.
Via
Investor's Business Daily
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
↗
September 12, 2023
A competitor's clinical trial stumble may be benefiting MoonLake.
Via
The Motley Fool
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
Casey's General Stores, Cognyte Software, Beauty Health And Other Big Stocks Moving Higher On Tuesday
↗
September 12, 2023
U.S. stocks traded lower, with the Dow Jones gaining around 90 points on Tuesday. Here are some big stocks recording gains in today’s session. Shengfeng Development Limited (NASDAQ: SFWL) shares jumped...
Via
Benzinga
Topics
Stocks
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
↗
September 12, 2023
The companies are both working on treatments for a rare skin disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 11, 2023
Via
Benzinga
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
September 06, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
August 31, 2023
Via
Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
↗
August 31, 2023
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
↗
August 31, 2023
Via
Benzinga
The 7 Most Promising Momentum Stocks to Own Now
↗
August 31, 2023
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
Via
InvestorPlace
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
↗
July 18, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile'
↗
July 17, 2023
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75
Via
Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
↗
July 17, 2023
Benzinga
Via
Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
↗
July 17, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
